



COVID-19 VACCINES

ISV VIRTUAL CONGRESS SERIES

3rd Congress
Aug 25, 2020

Registration

www.ISVCongress.org

CONTACT

PHONE:
1-508-856-1179

EMAIL:
Info@ISVCongress.org

Program Aug 25, 9:00am – 12:00 noon (ET)

9:00 am Welcome and Introductions
Chair: Shan Lu, UMass Medical School/ISV
Linda Klavinskis, King's College London/ISV
Introduction of ISV Virtual Congress

Opening Session (20 min talks + 5 min Q&A)

Chair: Shan Lu, ISV
9:05am Myron Cohen, UNC-Chapel Hill
mAbs for COVID-19: Treatment and Prevention
9:30am Lynda Stuart, Bill & Melinda Gates Foundation
COVID-19 Vaccine: How We Win the Race to
Billions of Doses

Scientific Session One (18 min talks + 7 min Q&A)

Part I: Protein Vaccines

Chair: Xavier Saelens, University of Ghent/ISV
9:55am Keith Chappell, The University of Queensland
Molecular Clamp Stabilized Recombinant Protein
Subunit Vaccine for COVID-19
10:20am John Shiver, Sanofi-GSK
Recombinant and mRNA Vaccine Candidates
Against COVID-19

Part II: Novel Vaccine Technologies

Chair: Anna-Lise Williamson, University of Cape Town/ISV
10:45am Jacqueline Miller, Moderna
Moderna's Coronavirus Vaccine: Early Clinical Data
and the COVE Phase III Efficacy and Safety Study
11:05am Brian Ward, Medicago
Development of Plant-Derived SARS-CoV-2 Virus-
Like Particle (CoVLP) Vaccine

Scientific Session Two (30 min panel discussion)

The Role of T and B Cell Responses and Vaccine Assay Standards
for Determining Efficacy

Moderator: Margret Liu, ProTherImmune/ISV
11:30am Alessandro Sette, La Jolla Institute for Immunology
Michel Nussenzweig, The Rockefeller University
Neil Almond, NIBSC

Wrap up and Future ISV Virtual Congresses

12:00pm Linda Klavinskis, ISV

ISV Virtual Congress Series Co-Chairs

Linda Klavinskis, Margaret Liu, Shan Lu / ISV
Senior Advisors

Nick Jackson / CEPI, Susan Barnett / BMGF

